---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000050"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:36:08.313331+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mineralys completes Launch-HTN enrollment ahead of schedule; topline data mid-H1 2025

## Summary
- Enrollment completed ahead of schedule in global Phase 3 Launch-HTN trial of lorundrostat for uncontrolled or resistant hypertension.
- Topline data now anticipated in mid first half of 2025, earlier than originally planned.
- Trial randomized patients to placebo, lorundrostat 50 mg QD, or 50 mg titrated to 100 mg QD; primary endpoint SBP change at 6 weeks.
- Company hosting virtual KOL event on Oct 30 to discuss unmet need and lorundrostat pivotal program.

## SEC filing metadata
- accession: 0001933414-24-000050
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000050/0001933414-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000050/mlys-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000050
- JSON: https://secwatch.observer/filing/0001933414-24-000050.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.